MR引导聚焦超声苍白球毁损术治疗帕金森病的安全性与可行性
一项为期1年的多中心开放标签试验纳入20例伴有运动波动和异动症的帕金森病患者,评估单侧MR引导聚焦超声苍白球内侧部毁损术。主要终点UDysRS总分在治疗后3个月改善59%,12个月改善43%,均持续显著优于基线;不良事件多为轻度和一过性,无事件符合FDA严重不良事件标准。
要点
- 单侧MRgFUS苍白球毁损术在20例PD患者中均成功完成,安全性可接受。
- UDysRS总分3个月改善59%、12个月改善43%,疗效持续至1年。
- 未用药状态下治疗侧MDS-UPDRS Part III运动症状3个月改善44.5%、12个月改善45.2%。
核心结论
- 本研究支持MRgFUS苍白球毁损术治疗伴有运动波动(包括异动症)的PD患者具有可行性和初步疗效。
- 初步数据支持继续研究,安慰剂对照盲法试验正在进行中。
研究设计与样本
- 1年多中心开放标签试验,纳入20例对左旋多巴有反应、存在不对称运动体征及运动波动(包括异动症)的PD患者。
- 干预为单侧MRgFUS毁损苍白球内侧部,主要终点为UDysRS评分较基线的变化。
主要发现
- 20例入组患者均成功完成超声消融操作。
- MRgFUS相关神经系统不良事件总体轻微且一过性:视野缺损1例、构音障碍4例(2例轻度、2例中度)、认知障碍1例、精细运动障碍2例、面部无力1例。
- 3例不良事件评为严重(2例一过性超声相关疼痛、1例恶心/呕吐),但无事件符合美国FDA严重不良事件标准。
- UDysRS总分(主要终点)3个月较基线改善59%(基线均值36.1,95%CI 4.88;3个月14.2,95%CI 5.72,p<0.0001),12个月改善43%(20.5,95%CI 7.39,p<0.0001)。
- 未用药状态下治疗侧MDS-UPDRS Part III运动症状3个月改善44.5%(基线均值20.0,95%CI 2.4;3个月10.6,95%CI 1.86,p<0.0001),12个月改善45.2%(10.4,95%CI 2.11,p>0.0001)。
临床怎么用
- 对于伴有运动波动和异动症、对左旋多巴有反应的PD患者,单侧MRgFUS苍白球毁损术可作为无创毁损选项加以评估。
- 治疗前需告知患者可能出现一过性构音障碍、视野缺损、精细运动障碍和面部无力等不良事件。
局限性
- 开放标签、非盲法设计,缺乏安慰剂对照。
- 样本量20例,属初步可行性研究,疗效需盲法对照试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Stereotactic radiofrequency pallidotomy has demonstrated improvement in motor fluctuations in patients with Parkinson's disease (PD), particularly levodopa (L-dopa)-induced dyskinesias. The authors aimed to determine whether or not unilateral pallidotomy with MR-guided focused ultrasound (MRgFUS) could safely improve Unified Dyskinesia Rating Scale (UDysRS; the primary outcome measure) scores over baseline scores in patients with PD. METHODS: Twenty patients with PD and L-dopa responsiveness, asymmetrical motor signs, and motor fluctuations, including dyskinesias, participated in a 1-year multicenter open-label trial of unilateral MRgFUS ablation of the globus pallidus internus. RESULTS: The sonication procedure was successfully completed in all 20 enrolled patients. MRgFUS-related adverse neurological events were generally mild and transient, including visual field deficit (n = 1), dysarthria (n = 4, 2 mild and 2 moderate), cognitive disturbance (n = 1), fine motor deficit (n = 2), and facial weakness (n = 1). Although 3 adverse events (AEs) were rated as severe (transient sonication-related pain in 2, nausea/vomiting in 1), no AE fulfilled US FDA criteria for a Serious Adverse Effect. Total UDysRS, the primary outcome measure, improved 59% after treatment (baseline mean score 36.1, 95% CI 4.88; at 3 months 14.2, 95% CI 5.72, p < 0.0001), which was sustained throughout the study (at 12 months 20.5, 95% CI 7.39, 43% improvement, p < 0.0001). The severity of motor signs on the treated side (Movement Disorder Society version of the United Parkinson's Disease Rating Scale [MDS-UPDRS] part III) in the "off" medication state also significantly improved (baseline mean score 20.0, 95% CI 2.4; at 3 months 10.6, 95% CI 1.86, 44.5% improvement, p < 0.0001; at 12 months 10.4, 95% CI 2.11, 45.2% improvement, p > 0.0001). The vast majority of patients showed a clinically meaningful level of improvement on the impairment component of the UDysRS or the motor component of the UPDRS, while 1 patient showed clinically meaningful worsening on the UPDRS at month 3. CONCLUSIONS: This study supports the feasibility and preliminary efficacy of MRgFUS pallidotomy in the treatment of patients with PD and motor fluctuations, including dyskinesias. These preliminary data support continued investigation, and a placebo-controlled, blinded trial is in progress. Clinical trial registration no.: NCT02263885 (clinicaltrials.gov).
引用
- Eisenberg HM, Krishna V, Elias WJ, et al. MR-guided focused ultrasound pallidotomy for Parkinson's disease: safety and feasibility. J Neurosurg. 2020. PMID: 33481557. doi:10.3171/2020.6.JNS192773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。